Nantes & Lyon (France) and Strasbourg (France) - VIVALIS, and Transgene, announced that the two companies entered into a commercial license and collaboration agreement to develop a process using the VIVALIS EB66 cell line suitable for the manufacturing of Transgene MVA-based therapeutic vaccines.